On August 23, 2021 Philochem, a wholly owned subsidiary of Philogen S.p.A., a publicly-listed company, InterX, Inc., a privately-owned company, and Scripps Research, a non-profit American medical research facility, reported the signature of a research collaboration to discover new small molecule therapeutics using Philochem’s and Scripps’ proprietary DNA-Encoded Chemical Library (DEL) technology and InterX´s proprietary computational chemical biology software platform (Press release, Philogen, AUG 23, 2021, View Source [SID1234586806]).

This collaboration brings together Nobel laureates Roger Kornberg and Michael Levitt with leading DEL technology scientists Richard Lerner and Dario Neri. The team will collaborate on the development of a best-in-class targeting agent for metastatic prostate cancer, a disease that affects millions of patients worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Richard Lerner is Institute Professor at Scripps Research, one of the world’s leading Institutions in chemical and biomedical research. He first postulated the principle of DEL technology in 1992.